S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:OCGN

Ocugen Competitors

$8.97
-1.49 (-14.24 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.40
Now: $8.97
$10.40
50-Day Range
$1.66
MA: $6.34
$15.81
52-Week Range
$0.17
Now: $8.97
$18.77
Volume35.70 million shs
Average Volume77.86 million shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.56

Competitors

Ocugen (NASDAQ:OCGN) Vs. ADPT, TWST, HALO, VIR, KOD, and IOVA

Should you be buying OCGN stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Ocugen, including Adaptive Biotechnologies (ADPT), Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Kodiak Sciences (KOD), and Iovance Biotherapeutics (IOVA).

Adaptive Biotechnologies (NASDAQ:ADPT) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Institutional & Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Adaptive Biotechnologies and Ocugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
Ocugen01302.75

Adaptive Biotechnologies presently has a consensus price target of $61.40, indicating a potential upside of 40.57%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Adaptive Biotechnologies' higher possible upside, research analysts plainly believe Adaptive Biotechnologies is more favorable than Ocugen.

Earnings & Valuation

This table compares Adaptive Biotechnologies and Ocugen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million71.48$-68,610,000.00($1.01)-43.25
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Profitability

This table compares Adaptive Biotechnologies and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
OcugenN/A-47.72%-30.78%

Summary

Adaptive Biotechnologies beats Ocugen on 8 of the 13 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Institutional & Insider Ownership

87.9% of Twist Bioscience shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Twist Bioscience and Ocugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Twist Bioscience11202.25
Ocugen01302.75

Twist Bioscience presently has a consensus price target of $133.3333, indicating a potential upside of 14.33%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Twist Bioscience's higher possible upside, research analysts plainly believe Twist Bioscience is more favorable than Ocugen.

Earnings & Valuation

This table compares Twist Bioscience and Ocugen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$90.10 million62.97$-139,930,000.00($3.00)-38.87
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Twist Bioscience has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Profitability

This table compares Twist Bioscience and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Twist Bioscience-155.31%-44.62%-35.49%
OcugenN/A-47.72%-30.78%

Summary

Ocugen beats Twist Bioscience on 8 of the 13 factors compared between the two stocks.

Halozyme Therapeutics (NASDAQ:HALO) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Halozyme Therapeutics and Ocugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics01902.90
Ocugen01302.75

Halozyme Therapeutics presently has a consensus price target of $42.9167, indicating a potential upside of 6.20%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Halozyme Therapeutics is more favorable than Ocugen.

Institutional & Insider Ownership

98.5% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 2.6% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Halozyme Therapeutics and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme Therapeutics10.78%24.29%4.08%
OcugenN/A-47.72%-30.78%

Risk and Volatility

Halozyme Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Earnings & Valuation

This table compares Halozyme Therapeutics and Ocugen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$195.99 million27.89$-72,240,000.00($0.50)-80.82
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen has lower revenue, but higher earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats Ocugen on 10 of the 13 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Ocugen and Vir Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocugen01302.75
Vir Biotechnology20502.43

Ocugen currently has a consensus target price of $4.80, indicating a potential downside of 46.49%. Vir Biotechnology has a consensus target price of $63.8571, indicating a potential upside of 60.97%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Ocugen.

Institutional & Insider Ownership

8.5% of Ocugen shares are owned by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are owned by institutional investors. 3.5% of Ocugen shares are owned by company insiders. Comparatively, 37.2% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ocugen and Vir Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OcugenN/A-47.72%-30.78%
Vir Biotechnology-339.61%-47.11%-39.44%

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its stock price is 256% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500.

Earnings and Valuation

This table compares Ocugen and Vir Biotechnology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OcugenN/AN/A$-20,240,000.00($1.48)-6.06
Vir Biotechnology$8.09 million626.86$-174,680,000.00($5.76)-6.89

Ocugen has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Summary

Ocugen beats Vir Biotechnology on 7 of the 13 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Ocugen and Kodiak Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OcugenN/AN/A$-20,240,000.00($1.48)-6.06
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-89.34

Kodiak Sciences is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Ocugen and Kodiak Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocugen01302.75
Kodiak Sciences17302.18

Ocugen currently has a consensus target price of $4.80, indicating a potential downside of 46.49%. Kodiak Sciences has a consensus target price of $129.1818, indicating a potential upside of 15.68%. Given Kodiak Sciences' higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Ocugen.

Profitability

This table compares Ocugen and Kodiak Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OcugenN/A-47.72%-30.78%
Kodiak SciencesN/A-32.32%-23.86%

Institutional & Insider Ownership

8.5% of Ocugen shares are owned by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are owned by institutional investors. 3.5% of Ocugen shares are owned by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its stock price is 256% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Summary

Kodiak Sciences beats Ocugen on 6 of the 10 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Ocugen and Iovance Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OcugenN/AN/A$-20,240,000.00($1.48)-6.06
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-19.98

Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ocugen and Iovance Biotherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocugen01302.75
Iovance Biotherapeutics02802.80

Ocugen currently has a consensus target price of $4.80, suggesting a potential downside of 46.49%. Iovance Biotherapeutics has a consensus target price of $50.10, suggesting a potential upside of 57.70%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Ocugen.

Profitability

This table compares Ocugen and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OcugenN/A-47.72%-30.78%
Iovance BiotherapeuticsN/A-50.64%-45.64%

Institutional and Insider Ownership

8.5% of Ocugen shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 3.5% of Ocugen shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Summary

Ocugen beats Iovance Biotherapeutics on 6 of the 11 factors compared between the two stocks.


Ocugen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$43.68-14.8%$6.08 billion$85.07 million-45.98Analyst Downgrade
High Trading Volume
Twist Bioscience logo
TWST
Twist Bioscience
1.4$116.62-11.5%$5.67 billion$90.10 million-31.10Gap Up
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.41-3.8%$5.47 billion$195.99 million252.56
Vir Biotechnology logo
VIR
Vir Biotechnology
1.6$39.67-5.3%$5.07 billion$8.09 million-16.81Analyst Report
Gap Up
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$111.67-3.2%$5.00 billionN/A-48.13Earnings Announcement
Analyst Report
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$31.77-7.6%$4.67 billionN/A-16.55Analyst Upgrade
High Trading Volume
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.06-0.1%$4.65 billion$503.70 million32.98Upcoming Earnings
Increase in Short Interest
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.43-2.0%$4.56 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.49-14.0%$4.26 billion$20,000.00-5.23
RLAY
Relay Therapeutics
1.8$39.99-3.5%$3.60 billionN/A0.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.